Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

ured by PSA, and that patient remains on study lasting 9 cycles. Of the three patients in Arm 2 of the study, one progressed on treatment, one discontinued treatment prior to evaluation, and one patient had a confirmed partial response and remains on study after 7 cycles.

In summary, the first five evaluable patients there were two confirmed durable partial responses and one patient with stable disease. No grade 3 or 4 adverse events were reported to date and the two responding patients remain on trial. This study is currently actively enrolling.

Phase 2 Trial of TPI 287 for Pancreatic Cancer Initiated

Tapestry also initiated in the third quarter a second Phase 2 trial to explore the activity of TPI 287 in advanced pancreatic cancer. The trial is a multi-center, open-label, single arm Phase 2 study for up to 65 patients with advanced stage, unresectable pancreatic cancer, who have failed a prior gemcitabine-containing chemotherapy regimen for their disease. The trial will be conducted in approximately 10 to 15 centers in the U.S., Europe and India. This study is currently actively enrolling.

Data Presented from Preclinical Studies at International Cancer Conference

Tapestry also presented preclinical data on TPI-287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The poster presentation outlined the results of a number of different assays that confirm the Company's earlier observations that TPI 287 is less sensitive in a variety of resistant cancer cell lines to MDR1 mediated efflux than other approved taxanes. MDR1 mediated drug efflux may be a primary cause of resistance to chemotherapy with taxanes. Also presented was data showing that TPI 287 is retained at higher levels in MDR1 expressing cell lines than either paclitaxel or IDN 5109, another taxane in development purported to be active in MDR1 expressing tumors. In addition, data was presented that demonstrated tumor growth inhibition o
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 01, 2015 National recruitment firm ... of Brad Allen as Head of Sales at Optimal ... system market. , Allen brings over 20 years ... at a number of companies including Dell Services Healthcare, ... experience were a perfect fit for accomplishing the goals ...
(Date:3/31/2015)... 2015 Eastern Kentucky University is ... bachelor’s of criminal justice degree programs by Nonprofitcollegesonline.com. ... inspiring ideas and high quality educational opportunities,” Editor ... University. We are confident that students will find ... is the site’s first “Students before Profits” list, ...
(Date:3/31/2015)... 2015   Mapi expands Pharmacovigilance and ... and global Risk Management strength with the expanded ... acquisition . Pharmacovigilance and ... global team that includes physicians, pharmacists, and numerous ... in navigating complex safety requirements throughout the product ...
(Date:3/31/2015)... 31, 2015 Today, Cryos International, the ... of their U.S. facilities and inventory from New York ... of experience, Cryos’ relocation is a reflection of their ... to Orlando was completed during the first weekend of ... taking place on April 6. The new facility in ...
Breaking Biology Technology:Slone Partners Fills Head of Sales at Optimal Medicine 2EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2
... decades X-ray crystallography has been fundamental in the development ... the structure and function of many biological molecules, including ... However, in order to obtain good data, large ... to grow. There also is the problem that ...
... SOUTH SAN FRANCISCO, Calif., Feb. 21, 2012 Onyx Pharmaceuticals, Inc. ... at four investor conferences in February and March. ... 2012 Citi Global Healthcare Conference on Monday, February 27, 2012 at ... Cowen and Company 32nd Annual Health Care Conference Onyx ...
... Inc. (Nasdaq: CDXS ), a developer of ... chemicals, and pharmaceutical intermediates, today announced that Peter Strumph, ... Jefferies Global Clean Technology Conference, to be held in ... 1:45 p.m. ET. A live webcast and replay will ...
Cached Biology Technology:Scientists learn how to 'out run damage' with imaging technique 2Onyx Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:3/12/2015)... Calif. , March 12, 2015 WHEN:Tuesday, ... Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , ... Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... order to compete in several different markets and ... is currently witnessing an uptrend. ...
(Date:3/10/2015)... 10, 2015   Tute Genomics , pioneer in ... by next-generation sequencing company PrimBio Research Institute ... targeted gene panel interpretation. PrimBio, a certified ... most current technologies to support the work of experts ... offers two types of exome sequencing services: 1) Targeted ...
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... Soybean production has continued to increase in the Northeast ... the crop and many experienced growers planting alongside corn crops. ... with a corn planter in 30-inch rows instead of 7.5-inch ... a Cornell University scientist, investigated the response of two soybean ...
... L. Boren announced today that OU is establishing an ... expertise to benefit Oklahoma and the nation, including emerging ... led by a national expert, who will be appointed ... million gift from Corix, a multi-utility infrastructure company, which ...
... grant totaling $2.2 million shows how the University of ... using technology to advance the cutting-edge field of personalized ... their genetic make-up. The grant also highlights the ... Institute (CCTSI) to bring scientific discoveries to the bedside ...
Cached Biology News:OU establishes a new water and sustainability institute 2OU establishes a new water and sustainability institute 3Personalizing medicine 2Personalizing medicine 3
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... Amplification Grade digests single- ... oligodeoxyribonucleotides. The specific activity ... I Amplification Grade is ... for absence of RNase ...
Biology Products: